Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $715.7 million.

  • Viking Therapeutics' Liabilities and Shareholders Equity fell 2120.31% to $715.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.1 billion, marking a year-over-year decrease of 1623.63%. This contributed to the annual value of $715.7 million for FY2025, which is 2120.31% down from last year.
  • As of Q4 2025, Viking Therapeutics' Liabilities and Shareholders Equity stood at $715.7 million, which was down 2120.31% from $739.4 million recorded in Q3 2025.
  • In the past 5 years, Viking Therapeutics' Liabilities and Shareholders Equity registered a high of $967.5 million during Q1 2024, and its lowest value of $150.9 million during Q1 2023.
  • Over the past 5 years, Viking Therapeutics' median Liabilities and Shareholders Equity value was $375.6 million (recorded in 2023), while the average stood at $492.4 million.
  • As far as peak fluctuations go, Viking Therapeutics' Liabilities and Shareholders Equity plummeted by 2574.51% in 2022, and later skyrocketed by 54118.63% in 2024.
  • Quarter analysis of 5 years shows Viking Therapeutics' Liabilities and Shareholders Equity stood at $210.7 million in 2021, then dropped by 20.0% to $168.5 million in 2022, then surged by 118.65% to $368.5 million in 2023, then surged by 146.5% to $908.3 million in 2024, then decreased by 21.2% to $715.7 million in 2025.
  • Its last three reported values are $715.7 million in Q4 2025, $739.4 million for Q3 2025, and $827.9 million during Q2 2025.